中国药物警戒 ›› 2025, Vol. 22 ›› Issue (11): 1258-1262.
DOI: 10.19803/j.1672-8629.20250648

• 法规与管理研究 • 上一篇    下一篇

《中华人民共和国药典》(2025年版)注射剂安全性检查法应用指导原则修订解读

徐琳1, 吴彦霖2,△, 裴宇盛2, 蔡彤2#, 华晓东1*   

  1. 1天津市药品检验研究院药理室,天津 300070;
    2中国食品药品检定研究院化学检定所药理室,北京 102629
  • 收稿日期:2025-09-12 出版日期:2025-11-15 发布日期:2025-11-14
  • 通讯作者: *华晓东,男,硕士,研究员,药检药理毒理。E-mail: hxd720527@126.com,#为共同通信作者。
  • 作者简介:徐琳,女,博士,助理研究员,药检药理毒理。Δ为并列第一作者。
  • 基金资助:
    国家重点研发计划(2024YFA1107301)

Interpretations of Amendments to Guidelines for Applications of Safety Tests for Injections in Chinese Pharmacopoeia 2025 Edition

XU Lin1, WU Yanlin2,△, PEI Yusheng2, CAI Tong2#, HUA Xiaodong1*   

  1. 1Division of Pharmacology, Tianjin Institutes for Drug Control, Tianjin 300070, China;
    2Division of Pharmacology, Institute for Chemical Drug Control, National Institutes for Food and Drug Control, Beijing 102629, China
  • Received:2025-09-12 Online:2025-11-15 Published:2025-11-14

摘要: 目的 解析《中华人民共和国药典》(以下简称《中国药典》)(2025年版)四部收载的9301注射剂安全性检查法应用指导原则,为其使用提供参考。方法 对比2020年版与2025年版《中国药典》中9301指导原则的修订内容,结合国内外相关资料对本次修订进行解读。结果 本次修订注重国际协调,明确安全性检查法设定原则,对致热物质检查及异常毒性检查等安全检测项目设立做修订,对与药品直接接触的料、辅料、包材联合表述,对具体实验细节进行规范。结论 本次修订的指导原则与国际药品标准制修订前沿动态接轨,充分发挥规范性和导向性作用,对提升注射剂质量安全水平有重要意义。

关键词: 注射剂, 安全性检查, 《中国药典》(2025年版)四部, 9301应用指导原则, 单核细胞活化反应, 重组C因子法, 异常毒性检查

Abstract: Objective To interpret the revised guidelines for applications of safety tests for injections in the Chinese Pharmacopoeia 2025 edition (Volume IV) in order to provide a reference for related applications. Methods The revisions in guidelines 9301 between the 2020 and 2025 editions of the Chinese Pharmacopoeia were compared and contrasted before the amendments were interpreted based on relevant literature at home and abroad. Results This revision focused on alignment with international practices. The principles about safety tests were specified, items for safety testing such as pyrogen testing and abnormal toxicity testing were revised, and details on experiments were elaborated. Raw materials, excipients, and packaging materials that came into direct contact with drugs were described together. Conclusion The revised guidelines have been made compatible with the formation of standards for medical products administration in other countries, and can contribute to standardization and guidance, which is of vital importance for quality control of injections.

Key words: Injections, Safety Test, Chinese Pharmacopoeia 2025 Edition (Volume IV), Guideline 9301, Monocyte Activation Test, Recombinant Factor C, Abnormal Toxicity Test

中图分类号: